Amneal Pharmaceuticals Q1 FY26 earnings call AMRX

Amneal Pharmaceuticals announced the strategic acquisition of Kashiv BioSciences to create a fully integrated global biosimilars leader, aiming to become the #1 affordable medicines company in the U.S. This transaction unlocks access to over $300 million of worldwide biologic loss of exclusivity over the next decade, leveraging Kashiv's deep R&D and manufacturing capabilities with Amneal's proven commercial scale. The deal is structured with a balanced mix of $750 million upfront consideration (50% cash, 50% equity) and up to $350 million in performance-based milestones, maintaining a disciplined financial profile with a clear path to deleverage below 3x by 2028.

Kashiv brings over 12 years of biologics platform development, with more than $900 million invested, 600+ employees, and 4 R&D and manufacturing sites in the U.S. and India. This platform supports 3 to 5 biosimilar developments annually, offering end-to-end capabilities from clone development to regulatory execution. Drug substance capacity is expected to scale from 26,000 liters in 2026 to 75,000 liters by 2028, with an annual capital expenditure of $30 million to $50 million for the next 2-3 years to achieve this expansion. This vertical integration is considered a competitive advantage, enabling faster execution and full economics.

The highly synergistic transaction is expected to generate $400 million to $500 million in cumulative financial synergies over time^⏳. These synergies primarily stem from capturing full economics from previously partnered assets by eliminating milestones and profit-sharing obligations, as well as realizing substantial tax benefits and incentives from Indian authorities. The combined company's net debt leverage ratio is projected to be 3.7x adjusted EBITDA at the end of 2026, with deleveraging expected to resume in 2027, targeting below 3x by 2028. Management expressed confidence in long-term targets, including 2030 revenues growing by approximately $1.2 billion (40%) and EPS by $0.70 (70%) over 2026.

Amneal reported strong preliminary Q1 FY26 results, characterized by robust top-line growth and exceptional bottom-line growth. Total net revenues reached $723 million, up 4% year-over-year. Adjusted EBITDA was $202 million, an increase of 19%, and adjusted EPS was $0.27, up 29%. The Affordable Medicines segment saw revenue grow 2% to $423 million, driven by strong performance in women's health and ADHD products, with segment gross margin improving to 47.3% (up 320 basis points). Specialty revenue increased 23% to $133 million, with CREXONT revenue at $21 million and Brekiya at $4.6 million, demonstrating strong market uptake.

The acquisition aligns with Amneal's long-term strategy to become a much larger, more diversified biopharmaceutical company by 2030, with over 400 retail and injectable medicines, 20+ biosimilars, and multiple specialty branded products. Management believes the industry is entering a 'golden era for biosimilars,' with the global market expected to grow from $40 billion today to $200 billion by 2035, driven by significant biologic loss of exclusivity. Biosimilars are seen as the next major wave of affordable medicines, having saved the U.S. healthcare system an estimated $20 billion in 2024.

The combined entity will have a portfolio of 20+ biosimilars targeting over $100 billion in U.S. opportunity. Key near-term catalysts include the expected Q3 approval of lanreotide, a high-value partner asset, and the anticipated year-end approval for biosimilar Xolair, which will now capture full value for Amneal. The pipeline also includes additional approvals in 2028 and 2029 for biosimilars like ORENCIA and CIMZIA, representing meaningful future growth drivers. The portfolio is designed to be balanced and durable, including both large market opportunities and niche products with fewer competitors.